Scarica l'app Stockscreener
5.64
33.88%
-2.89
Dopo l'orario di chiusura:
5.80
0.16
+2.84%
Precedente Chiudi:
$8.53
Aprire:
$6.45
Volume 24 ore:
9.13M
Relative Volume:
20.55
Capitalizzazione di mercato:
$281.40M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
-27.32%
1M Prestazione:
-3.75%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$5.27
$6.80
Intervallo di 1 settimana:
$5.27
$8.5498
Portata 52W:
$5.27
$8.5498
Helus Pharma Inc Stock (HELP) Company Profile
Nome
Helus Pharma Inc
Settore
Industria
Telefono
-
Indirizzo
-
Compare HELP vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
HELP
Helus Pharma Inc
|
5.64 | 425.60M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.14 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Helus Pharma Inc Stock (HELP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-02 | Iniziato | Jefferies | Buy |
| 2025-03-13 | Iniziato | Guggenheim | Buy |
| 2021-11-19 | Downgrade | Maxim Group | Buy → Hold |
Helus Pharma Inc Borsa (HELP) Ultime notizie
Helus Pharma’s top-line Phase II data signal detection study for HLP004 - The Pharma Letter
Helus Pharma Stock Tumbles As Anxiety Drug Study Disappoints - Benzinga
Helus Pharma Announces Topline Results in Phase 2 Signal Detection Study for HLP004 in Patients with Generalized Anxiety Disorder - Investing News Network
HELP Stock Tanks 22% Despite Strong Phase 2 Results For Anxiety Treatment: Retail Buys The Dip Ignoring Market’s Pessimism - Stocktwits
Helus Pharma (HELP) Shares Drop Despite Positive Phase 2 Trial Results - GuruFocus
Helus Pharma (HELP) Reports Positive Phase 2 Study Results for A - GuruFocus
Cybin’s Helus Pharma Posts Strong Phase 2 Data for HLP004 in Hard-to-Treat Anxiety - TipRanks
Helus stock falls on data for anxiety therapy (HELP:NASDAQ) - Seeking Alpha
Helus Pharma announces topline results in phase 2 signal detection study for Hlp004 in patients with generalized anxiety disorder - marketscreener.com
Helus Pharma Announces Topline Results In Phase 2 Signal Detection Study For Hlp004 In Patients With Generalized Anxiety Disorder - TradingView
Experimental anxiety drug helps 67% of hard-to-treat patients - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Helus Pharma (HELP) Price Target Raised by HC Wainwright & Co. | - GuruFocus
Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments - The AI Journal
Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS Disorders - The Malaysian Reserve
From Lab to Clinic: Five CNS Companies Advancing Neuroscience Treatments - Baystreet.ca
Helus Pharma appoints Dr. Freda Lewis-Hall to board of directors - Investing.com India
HELUS Pharma: Transitioning From Psychedelic Research To Late-Stage Clinical Neuroscience - Seeking Alpha
Helus Pharma (Nasdaq: HELP) brings former Pfizer CMO Lewis-Hall onto board - Stock Titan
Helus Pharma appoints former Pfizer chief medical officer to board of directors - marketscreener.com
Helus Pharma Appoints Former Pfizer Chief Medical Officer Dr. Freda Lewis-Hall to Board of Directors & Chair of the Scientific Advisory Committee - Toronto Star
Magic Mushrooms, Hard Cash: Compass Pathways' Trial Win, Fast Raise - Finviz
Cybin (Helus Pharma) Names Veteran Pharma Executive Michael Cola as CEO to Drive CNS Growth - The Globe and Mail
HELP Stock Price and Chart — NEO:HELP - TradingView
Jeffries Highlight Cybin D/B/A Helus Pharma (HELP)'s Science-Driven Psilocybin Therapies as Key Growth Drivers - Finviz
Jeffries Highlight Cybin D/B/A Helus Pharma (HELP)’s Science-Driven Psilocybin Therapies as Key Growth Drivers - Yahoo Finance
Industry veteran Michael Cola named Cybin (CYBN) chief executive - Stock Titan
Psychedelics stocks rise as Compass’ psilocybin drug heads to FDA - BioPharma Dive
Helus Pharma reports positive phase 2a trial results for depression drug - Investing.com Australia
Cybin stock surges after positive Phase 2a trial results for depression drug - Investing.com
HELP SEC FilingsCybin Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Cybin Inc.Common Stock (Nasdaq:HELP) Stock Quote - The Chronicle-Journal
HELP Stock Rallies After Experimental Depression Drug Reduces Symptoms In Study: Retail Thinks Its ‘Time To Buy More’ - Stocktwits
Helus gains on published data for psychedelic drug (HELP) - Seeking Alpha
Nature Medicine Publishes Helus Pharma's Randomized, Placebo-Controlled Phase 2a Trial of SPL026 in Major Depressive Disorder - Investing News Network
Nature Medicine Publishes Helus Pharma’s Randomized, Placebo-Controlled Phase 2a Trial of SPL026 in Major Depressive Disorder - Toronto Star
Helus Pharma To Report Phase 2 Data For HLP004 In Generalized Anxiety Disorder This Quarter - Nasdaq
Helus Pharma (HELP) Advances Neuro Portfolio with Robust Financi - GuruFocus
HELUS Pharma Reports Third Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights - Investing News Network
Cybin (Helus Pharma) Posts Higher Assets, Equity and Losses in Q3 FY2026 SEC Filing - TipRanks
Helus Pharma (NASDAQ: HELP) widens loss while sharply increasing cash - Stock Titan
Helus Pharma appoints Michael Cola as CEO - The Pharma Letter
HELUS PHARMA NAMES MICHAEL COLA AS CEO FOR NEXT PHASE OF GROWTH - Bernama
Helus Pharma Names Michael Cola As CEO For Next Phase Of GrowthBERNAMA - BERNAMA - Malaysian National News Agency
Helus Pharma Inc Azioni (HELP) Dati Finanziari
Non sono disponibili dati finanziari per Helus Pharma Inc (HELP). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
3.69%
0.71%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):